Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme’s Gardasil shows efficacy among males

Merck Sharpe and Dohme’s Gardasil shows efficacy among males

4th February 2011

Merck Sharpe and Dohme has published data from a study that demonstrates the efficacy of its human papillomavirus (HPV) drug Gardasil among male patients.

Data from a phase III study featured in the New England Journal of Medicine shows that the drug demonstrated an 89 percent success rate in preventing genital warts from HPV types 6 and 11 among men aged between 16 and 26.

Gardasil has been available since 2006 for the prevention of cervical, vulvar, vaginal and anal cancers among women and was also ratified as an anal cancer and anal intraepithelial neoplasia treatment for men last December.

The new data represents the first time an HPV vaccine been proven to be efficacious among male patients for this indication.

Dr Anna Giuliano of the Moffitt Cancer in Tampa, Florida, who was the study's lead author, said: "This publication … underscores the importance of vaccinating both males and females to help prevent certain HPV-related diseases."

Last month, Merck Sharpe and Dohme agreed a deal with Parexel to support its development of a variety of new biosimilar drugs.ADNFCR-8000103-ID-800385656-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.